MA29444B1 - Antagonistes npy, preparation et utilisations - Google Patents
Antagonistes npy, preparation et utilisationsInfo
- Publication number
- MA29444B1 MA29444B1 MA30359A MA30359A MA29444B1 MA 29444 B1 MA29444 B1 MA 29444B1 MA 30359 A MA30359 A MA 30359A MA 30359 A MA30359 A MA 30359A MA 29444 B1 MA29444 B1 MA 29444B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- preparation
- npy
- present
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE DE NOUVEAUX COMPOSÉS, LEUR PRÉPARATION ET LEURS UTILISATIONS, NOTAMMENT THÉRAPEUTIQUES. ELLE CONCERNE PLUS PARTICULIÈREMENT DES COMPOSÉS DÉRIVÉS PRÉSENTANT AU MOINS DEUX CYCLES AROMATIQUES, LEUR PRÉPARATION ET LEURS UTILISATIONS, NOTAMMENT DANS LE DOMAINE DE LA SANTÉ HUMAINE OU ANIMALE. CES COMPOSÉS ONT UNE AFFINITÉ POUR LES RÉCEPTEURS BIOLOGIQUES DU NEUROPEPTIDE Y, NPY, PRÉSENTS DANS LES SYSTÈMES NERVEUX CENTRAL ET PÉRIPHÉRIQUE. LES COMPOSÉS SELON L'INVENTION SONT PRÉFÉRENTIELLEMENT DES ANTAGONISTES DE NPY ET PLUS PARTICULIÈREMENT DES ANTAGONISTES DU SOUS-TYPE NPY Y1, ET SONT DONC UTILISABLES DANS LE TRAITEMENT THÉRAPEUTIQUE OU PROPHYLACTIQUE DE TOUT DÉSORDRE IMPLIQUANT NPY. LA PRÉSENTE INVENTION CONCERNE ÉGALEMENT DES COMPOSITIONS PHARMACEUTIQUES COMPRENANT DE TELS COMPOSÉS, LEUR PRÉPARATION ET LEURS UTILISATIONS, AINSI QUE DES MÉTHODES DE TRAITEMENT UTILISANT LESDITS COMPOSÉS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0503795A FR2884516B1 (fr) | 2005-04-15 | 2005-04-15 | Antagonistes npy, preparation et utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29444B1 true MA29444B1 (fr) | 2008-05-02 |
Family
ID=35447654
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30359A MA29444B1 (fr) | 2005-04-15 | 2007-11-07 | Antagonistes npy, preparation et utilisations |
Country Status (19)
Country | Link |
---|---|
US (1) | US20090233910A1 (fr) |
EP (1) | EP1879887A2 (fr) |
JP (1) | JP2008538749A (fr) |
KR (1) | KR20080009112A (fr) |
CN (1) | CN101198604A (fr) |
AP (1) | AP2007004218A0 (fr) |
AU (1) | AU2006234413A1 (fr) |
CA (1) | CA2604773A1 (fr) |
CR (1) | CR9514A (fr) |
EA (1) | EA200800157A1 (fr) |
EC (1) | ECSP077894A (fr) |
FR (1) | FR2884516B1 (fr) |
IL (1) | IL186601A0 (fr) |
MA (1) | MA29444B1 (fr) |
MX (1) | MX2007012847A (fr) |
NI (1) | NI200700260A (fr) |
NO (1) | NO20075322L (fr) |
TN (1) | TNSN07376A1 (fr) |
WO (1) | WO2006108965A2 (fr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR051780A1 (es) * | 2004-11-29 | 2007-02-07 | Japan Tobacco Inc | Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos |
GB0512091D0 (en) * | 2005-06-14 | 2005-07-20 | Novartis Ag | Organic compounds |
EP1954287B2 (fr) * | 2005-10-31 | 2016-02-24 | Merck Sharp & Dohme Corp. | Inhibiteurs de la cetp |
AU2007208151B2 (en) | 2006-01-25 | 2013-04-18 | Synta Pharmaceuticals Corp. | Vinyl-phenyl derivatives for inflammation and immune-related uses |
WO2008083124A1 (fr) | 2006-12-28 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | Composés d'hétérocycloalkyloxybenzamide n-substitués, et procédés d'utilisation |
CA2685029A1 (fr) * | 2007-04-26 | 2008-11-06 | Avalon Pharmaceuticals | Composes polycycliques et leurs utilisations |
US20090176796A1 (en) | 2007-04-27 | 2009-07-09 | Purdue Pharma L. P. | Trpv1 antagonists including amide substituent and uses thereof |
JP2008303155A (ja) * | 2007-06-06 | 2008-12-18 | Ube Ind Ltd | N−(ω−フルオロアルキル)環状アミン化合物の製法、並びに新規なN−(4−フルオロブチル)環状アミン化合物及びその製法 |
JP2009035537A (ja) * | 2007-07-10 | 2009-02-19 | Nippon Synthetic Chem Ind Co Ltd:The | N−置換アニリン誘導体及び1−置換インドール誘導体の製造方法 |
WO2010036908A1 (fr) * | 2008-09-26 | 2010-04-01 | Eisai R & D Management Co., Ltd. | Utilisation de composés benzoxazole dans le traitement du paludisme |
CN102272120B (zh) * | 2008-11-07 | 2013-12-25 | H.隆德贝克有限公司 | 生物活性酰胺 |
EP2404902A1 (fr) * | 2009-03-05 | 2012-01-11 | Shionogi&Co., Ltd. | Dérivés de la pipéridine et de la pyrrolidine dotés d'un antagonisme pour les récepteurs npy y5 |
US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
PE20141531A1 (es) | 2011-06-22 | 2014-10-23 | Purdue Pharma Lp | Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos |
JP6263469B2 (ja) | 2011-07-15 | 2018-01-17 | ノバルティス アーゲー | アザ二環式ジ−アリールエーテルの塩およびその製造方法またはその前駆体の製造方法 |
RU2014124531A (ru) * | 2012-01-25 | 2016-04-10 | Демеркс, Инк. | (1r,4r) 7-оксо-2-азабицикло[2.2.2]окт-5-ен и его производные |
JP6667458B2 (ja) * | 2014-05-21 | 2020-03-18 | ソルベイ スペシャルティ ポリマーズ ユーエスエー, エルエルシー | 安定剤化合物 |
CA2978518C (fr) | 2015-03-27 | 2023-11-21 | Nathanael S. Gray | Inhibiteurs de kinases cycline-dependantes |
WO2016187667A1 (fr) * | 2015-05-27 | 2016-12-01 | Novogen Limited | Indoles fonctionnalisés et substitués utilisés en tant qu'agents anti-cancéreux |
CA2996978A1 (fr) * | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinases cycline-dependantes |
JP2017137259A (ja) * | 2016-02-03 | 2017-08-10 | 株式会社Ihi | 有機化合物の製造方法 |
CA3014395A1 (fr) | 2016-02-19 | 2017-08-24 | Phoenix Molecular Designs | Derives de carboxamide utiles en tant qu'inhibiteurs de rsk |
CN106543089A (zh) * | 2016-11-04 | 2017-03-29 | 山东铂源药业有限公司 | 一种达沙替尼中间体的合成方法 |
CN107892656A (zh) * | 2017-10-27 | 2018-04-10 | 苏州盖德精细材料有限公司 | 一种2,5‑二氨基苯乙醇的制备方法 |
AU2020349516A1 (en) * | 2019-09-17 | 2022-03-17 | Bial-R&D Investments, S.A. | Substituted imidazole carboxamides and their use in the treatment of medical disorders |
KR102234530B1 (ko) * | 2020-09-01 | 2021-03-31 | 대한민국 | 신규 톨트라주릴 유도체 및 이를 포함하는 쿠도아충 예방·치료를 위한 약학 조성물 |
CN115215787A (zh) * | 2021-04-19 | 2022-10-21 | 中国科学院上海药物研究所 | 生长抑素受体5拮抗剂及其用途 |
CN117003672B (zh) * | 2023-08-09 | 2024-05-28 | 湖南正量工程技术有限公司 | 一种boc-4,4’-二硝基二苯胺的制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06248153A (ja) * | 1993-03-01 | 1994-09-06 | Shin Etsu Chem Co Ltd | 難燃樹脂組成物 |
SE9703414D0 (sv) * | 1997-09-23 | 1997-09-23 | Astra Ab | New compounds |
CN1311773A (zh) * | 1998-06-08 | 2001-09-05 | 先灵公司 | 神经肽y5受体拮抗剂 |
JP2000287697A (ja) * | 1999-02-05 | 2000-10-17 | Shionogi & Co Ltd | Npy受容体親和性を有するラクトン誘導体 |
GB9910577D0 (en) * | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
DE10038007A1 (de) * | 2000-08-04 | 2002-02-14 | Bayer Ag | Neue Amino-und Amido-Diphenylether für Arzneimittel |
EP1322628A2 (fr) * | 2000-09-14 | 2003-07-02 | Schering Corporation | Antagonistes du recepteur y.y5 de neuropeptide d'urease substitue |
MXPA04000707A (es) * | 2001-07-26 | 2004-04-20 | Schering Corp | Nuevos antagonistas del receptor y5 del neuropeptido y referencia cruzada a solicitudes relacionadas. |
AU2003210305B2 (en) * | 2002-02-28 | 2006-07-06 | F. Hoffmann-La Roche Ag | Thiazole derivatives as NPY receptor antagonists |
MXPA05000055A (es) * | 2002-07-11 | 2005-04-08 | Aventis Pharma Gmbh | Acilureas sustituidas con urea y uretano, metodos para su produccion y su uso. |
EP1635773A2 (fr) * | 2003-06-06 | 2006-03-22 | Merck & Co., Inc. (a New Jersey corp.) | Polytherapie pour le traitement de l'hypertension |
-
2005
- 2005-04-15 FR FR0503795A patent/FR2884516B1/fr not_active Expired - Fee Related
-
2006
- 2006-04-14 NI NI200700260A patent/NI200700260A/es unknown
- 2006-04-14 EA EA200800157A patent/EA200800157A1/ru unknown
- 2006-04-14 CN CNA2006800212757A patent/CN101198604A/zh active Pending
- 2006-04-14 MX MX2007012847A patent/MX2007012847A/es unknown
- 2006-04-14 WO PCT/FR2006/000829 patent/WO2006108965A2/fr active Application Filing
- 2006-04-14 JP JP2008505929A patent/JP2008538749A/ja active Pending
- 2006-04-14 US US11/918,470 patent/US20090233910A1/en not_active Abandoned
- 2006-04-14 AU AU2006234413A patent/AU2006234413A1/en not_active Abandoned
- 2006-04-14 CA CA002604773A patent/CA2604773A1/fr not_active Abandoned
- 2006-04-14 EP EP06743700A patent/EP1879887A2/fr not_active Withdrawn
- 2006-04-14 AP AP2007004218A patent/AP2007004218A0/xx unknown
- 2006-04-14 KR KR1020077026216A patent/KR20080009112A/ko not_active Application Discontinuation
-
2007
- 2007-10-05 TN TNP2007000376A patent/TNSN07376A1/en unknown
- 2007-10-11 IL IL186601A patent/IL186601A0/en unknown
- 2007-10-17 NO NO20075322A patent/NO20075322L/no not_active Application Discontinuation
- 2007-11-07 MA MA30359A patent/MA29444B1/fr unknown
- 2007-11-13 EC EC2007007894A patent/ECSP077894A/es unknown
- 2007-11-13 CR CR9514A patent/CR9514A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20090233910A1 (en) | 2009-09-17 |
ECSP077894A (es) | 2008-03-26 |
EP1879887A2 (fr) | 2008-01-23 |
FR2884516A1 (fr) | 2006-10-20 |
WO2006108965A2 (fr) | 2006-10-19 |
NI200700260A (es) | 2009-03-03 |
EA200800157A1 (ru) | 2008-04-28 |
CN101198604A (zh) | 2008-06-11 |
WO2006108965A3 (fr) | 2007-03-29 |
MX2007012847A (es) | 2008-03-25 |
AP2007004218A0 (en) | 2007-10-31 |
KR20080009112A (ko) | 2008-01-24 |
IL186601A0 (en) | 2008-01-20 |
NO20075322L (no) | 2008-01-11 |
TNSN07376A1 (en) | 2009-03-17 |
JP2008538749A (ja) | 2008-11-06 |
CA2604773A1 (fr) | 2006-10-19 |
CR9514A (es) | 2008-08-26 |
FR2884516B1 (fr) | 2007-06-22 |
AU2006234413A1 (en) | 2006-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29444B1 (fr) | Antagonistes npy, preparation et utilisations | |
MA30557B1 (fr) | Composés de pyrrolopyrimidine et leurs utilisations. | |
MA30333B1 (fr) | Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete. | |
MA34474B1 (fr) | Agonistes de gpr40 | |
MA32035B1 (fr) | Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4 | |
TNSN07305A1 (fr) | Agonistes de pyy et leurs utilisations | |
MA31167B1 (fr) | Inhibiteurs de l'activite de akt | |
MA27548A1 (fr) | Inhibiteurs heterocycliques beta-amines de la dipeptidyl peptidase pour le traitement ou la prevention du diabete. | |
MA32131B1 (fr) | Antagonistes aminoalkylbiphényle n, n' disubstitués des récepteurs d2 de la prostaglandine | |
MA33606B1 (fr) | Dérivés de pyrimidine en tant qu'inhibiteurs de protéine tyrosine kinase 2 | |
EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
MA27556A1 (fr) | Derives de phenylalanine comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete | |
MA32684B1 (fr) | Dérivés de picolinamide en tant qu'inhibiteurs de kinase | |
MA32887B1 (fr) | Aminotetrahydropyranes en tant qu'inhibiteurs de dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete | |
EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
EA200701036A1 (ru) | Лактамные соединения и их применение в качестве фармацевтических препаратов | |
MA33419B1 (fr) | Composés et compositions pour le traitement de maladies parasitaires | |
ATE447574T1 (de) | 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes | |
ATE509019T1 (de) | Benzodiazepinspirohydantoine als cgrp- rezeptorantagonisten | |
MA29140B1 (fr) | Dérivés de quinoléine hétéroaromatiques et leur utilisation comme inhibiteurs de PDE10 | |
ATE463492T1 (de) | Kondensierte indole als dipeptidyl-peptidase- hemmer zur behandlung oder prävention von diabetes | |
BRPI0517481A (pt) | método para tratar, controlar ou evitar uma doença ou distúrbio parasìtico protozoário, e, composição farmacêutica | |
MA27347A1 (fr) | Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese | |
MA31683B1 (fr) | Composes et procedes pour moduler fxr | |
TW200612926A (en) | Compounds and compositions as ppar modulators |